AUTHORS
Stephan Hutter, PhD, Sandra Huber, PhD2, Alessandro Baldi, PhD3, Anna Stengel, PhD4, Manja Meggendorfer, PhD5, Torsten Haferlach, MD, PhD6, Gregor Hoermann, MD7
AFFILIATIONS
1 MLL Munich Leukemia Laboratory, Munich, Germany
2 MLL Munich Leukemia Laboratory, Munich, Germany
3 MLL Munich Leukemia Laboratory, Munich, Germany
4 MLL Munich Leukemia Laboratory, Munich, Germany
5 MLL Munich Leukemia Laboratory, Munich, Germany
6 MLL Munich Leukemia Laboratory, Munich, Germany
7 MLL Munich Leukemia Laboratory, Munich, Germany
ABSTRACT
Background:
TP53 mutations (mut) frequently occur in myeloid neoplasms (MN) like myelodysplastic neoplasms (MDS) or acute myeloid leukemia (AML), are associated with adverse prognosis and have been suggested as entity-defining. Disease progression and genomic instability in TP53-mut patients is amongst others impacted by the allelic state, specifically bi-allelic inactivation, and variant allele fraction (VAF). Thus, current classification systems differ regarding TP53-mut as entity-definition in terms of the allelic state (either multi-hit or bi-allelic, i.e. inactivation of a second allele via second TP53-mut, del(17p) or copy-neutral loss of heterozygosity (CN-LOH)) and VAF cut-off. In addition, a multi-mutated state of TP53 can also occur in a multi-clonal background, i.e. mono-allelic TP53-mut in different (sub-)clones. Addressing these aspects will be crucial for harmonizing disease classifications.
Aim:
Evaluate the frequency and relevance of the different types of TP53-mut across AML and MDS and address related technical challenges to simplify currently discussed entity-defining inclusion criteria.
Methods:
We retrospectively evaluated peripheral blood or bone marrow samples of 3,010 TP53-mut patients diagnosed as MDS (n=1,509) or AML (n=1,501). TP53-mut were analyzed by either panel or whole genome sequencing (WGS). Status of del(17p) was established through sequencing (panels with copy-number spike-in or WGS), FISH, and/or chromosomal banding. CN-LOH status was assessed by sequencing (MDS: n=438; AML: n=151). Configuration (cis or trans) of TP53-mut pairs ≤180bp apart was established by analyzing fragment cooccurrence in high-coverage (>1,500x) BAM files (MDS: n=62; AML: n=67).
Results:
Most TP53-mut cases had only one TP53-mut (MDS: 75.6%, AML: 78.2%); an accompanying del(17p) was more frequent in AML (37.0% vs. 17.7% in MDS), while accompanying CN-LOH was more common in MDS (23.3% vs. 9.4% in AML). Occurrences of del(17p) or CN-LOH in conjunction with multiple TP53-mut were only rarely observed (<5%). Taken together, 66.4% of TP53-mut MDS and 68.1% of AML cases showed multiple TP53 aberrations. TP53-mut VAF ≥10% were observed in 74.1% of MDS and 90.9% of AML cases. VAF >50% is often used as proxy for determining bi-allelic state. Indeed, there was a strong association of TP53-mut >50% VAF with the presence of CN-LOH (72.1% concordance in MDS; 90.3% in AML). Formally, multiple TP53-mut without del(17p) or CN-LOH (MDS: 21.8%, AML: 17.5%) can only be viewed as bi-allelic if the TP53-mut affect different alleles (trans configuration). We found that neighboring TP53-mut pairs in 100% of cases occurred exclusively in trans suggesting that cis configuration of multi-TP53-mut is extremely rare. To take into account the possibility of multi-clonal, mono-allelic TP53-mut, we used a VAFs sum of >50% to classify 37.8% of multi-TP53-mut MDS and 71.3% AML as unambiguously bi-allelic, while the remaining cases (a total of 13% of TP53-mut MDS and 5% AML) were considered probable bi-allelic. Overall survival (OS) analysis of cases with VAF ≥10% showed similarly poor survival for bi-allelic AML, bi-allelic MDS, and mono-allelic AML (median OS: 0.2, 0.8, and 0.6 years) in contrast to mono-allelic MDS (median OS: 4.3 years, p<0.001 in all comparisons) which was comparable to MDS with TP53-mut VAF <10% (median OS: 4.4 years). Subgroup analysis within bi-allelic MDS indicated a slightly worse OS of patients with del(17p)/CN-LOH compared to multi-mutated MDS (median OS: 0.4 vs. 1.2 years, p=0.04).
Conclusions:
The allelic state of TP53-mut can be confirmed or inferred from standard diagnostic data in the majority of TP53-mut MN: multi-hit is a feasible proxy for bi-allelic in cases with VAF ≥10%, specific analysis of CN-LOH is recommended, while phasing of multiple TP53-mut can be omitted. OS data support the concept of a common category of MN with bi-allelic TP53 inactivation (VAF ≥10%) while discriminating mono-allelic TP53 mutated MDS from AML. Whether the possibility of mimicking bi-allelic MDS in some patients by multiple mono-allelic TP53-mut in different (sub-)clones has a clinical impact is subject of forthcoming single cell sequencing studies. In summary, our data give guidance for practical technical considerations in a harmonized definition of MN with bi-allelic TP53 inactivation which is of utmost importance to foster the development and utilization of new targeting concepts in this dismal group of patients.
DISCLOSURES
Gregor Hoermann, MD: MLL Munich Leukemia Laboratory - Current Employment